Want to see MRVI full AI Analyst Report?
Top Page
Maravai Lifesciences Holdings
(NASDAQ:MRVI)
Select Model
Select Model
Rating:65Neutral
Price Target:
$6.50
▲(91.74% Upside)
Action:Reiterated
Date:06/04/26
The score is driven by strong earnings-call execution/guidance upgrades and supportive technical momentum, reinforced by improved balance-sheet flexibility from refinancing. Offsetting these positives, the financial statements still show sustained losses and renewed TTM cash burn, and valuation is less supportive due to a negative P/E and no dividend yield.
Positive Factors
TriLink recurring consumables and GMP conversion momentum
TriLink’s high-share, recurring consumables franchise benefits as customer programs move RUO→GMP. Forecasted GMP customer growth and multiple RUO-to-GMP conversions support durable demand and repeat purchasing as customers scale from R&D into clinical and commercial manufacturing.
Negative Factors
Persistent GAAP losses and deeply negative returns on equity
Sustained GAAP losses and very negative ROE indicate the company’s capital base is not generating profits. This structural profitability shortfall weakens the balance sheet over time, limits internal funding for growth, and increases reliance on external capital unless profitability turns durable.
Read all positive and negative factors
Positive Factors
Negative Factors
TriLink recurring consumables and GMP conversion momentum
TriLink’s high-share, recurring consumables franchise benefits as customer programs move RUO→GMP. Forecasted GMP customer growth and multiple RUO-to-GMP conversions support durable demand and repeat purchasing as customers scale from R&D into clinical and commercial manufacturing.
Read all positive factors
Maravai Lifesciences Holdings Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyMaravai Lifesciences Holdings (MRVI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.54B
Dividend YieldN/A
Average Volume (3M)2.92M
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue Growth-15.35%
EPS Growth37.09%
CountryUS
Employees435
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.07
Shares Outstanding147,506,160
10 Day Avg. Volume3,084,133
30 Day Avg. Volume2,916,748
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)2.22
Price to Sales (P/S)2.54
P/FCF Ratio-6.67
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue7.56
Enterprise Value/Gross Profit26.06
Enterprise Value/Ebitda-14.89
Forecast
1Y Price Target
$5.67Price Target Upside67.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.11
Revenue Forecast (FY)$210.43M
Maravai Lifesciences Holdings Business Overview & Revenue Model
Company Description
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse prod...
How the Company Makes Money
Maravai makes money by selling life science products and services to biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), diagnostics developers, and research customers. Revenue is generated primarily from: (1...
Maravai Lifesciences Holdings Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call communicated strong operational and financial progress: robust revenue growth (41% YoY), sizable adjusted EBITDA improvement, first positive free cash flow since 2024, raised full-year revenue and EBITDA guidance, product adoption (ModTail) and R&D/IP milestones. Challenges discussed were largely execution and timing related (China/distributor ordering, quarter-to-quarter lumpiness, academic demand weakness) and some near-term limitations from new GMP launches and elevated debt. Overall, positives—driven by mix shift toward higher-margin GMP/discovery consumables, realized cost savings, and improving cash generation—outweigh the highlighted risks.Positive Updates
Strong Top-Line Growth
Total Q1 revenue of $65.8M, up 41% year-over-year; base business revenue (ex-COVID CleanCap) up 10% YoY.
Negative Updates
China and APAC Softness / Timing
Cygnus revenue grew only ~1% YoY and China contributed just 7% of base revenue; Q1 softness in China attributed to distributor ordering timing and lower APAC mix, viewed as timing-related but caused quarter variability.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Top-Line Growth
Total Q1 revenue of $65.8M, up 41% year-over-year; base business revenue (ex-COVID CleanCap) up 10% YoY.
Read all positive updates
Company Guidance
Management raised full-year 2026 guidance, now targeting total revenue of $205 million to $215 million (growth of ~10%–16% vs. 2025) driven by TriLink (now expected to grow in the high teens) and Cygnus (low- to mid-single-digit growth), with TriLink GMP customers forecast to grow ~22% in 2026 (nine RUO-to-GMP transitions, two already converted); they substantially increased full‑year adjusted EBITDA to $30 million–$32 million (an improvement of ~$61M–$63M year‑over‑year), expect gross margin expansion of greater than 1,300 basis points, and reiterated they expect positive free cash flow for the remainder of the year; commentary noted no additional high‑volume COVID CleanCap revenue is expected in 2026 (but an endemic baseline of $10M–$20M is viewed as reasonable long-term).Maravai Lifesciences Holdings Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
58
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 204.73M | 185.74M | 259.19M | 288.94M | 883.00M | 799.24M |
| Gross Profit | 59.37M | 33.39M | 108.31M | 140.20M | 714.04M | 658.68M |
| EBITDA | -103.91M | -147.11M | -156.92M | 712.41M | 609.99M | 585.78M |
| Net Income | -104.56M | -130.77M | -144.85M | -119.03M | 220.21M | 182.04M |
Balance Sheet | ||||||
| Total Assets | 713.22M | 770.58M | 1.01B | 1.49B | 2.28B | 1.92B |
| Cash, Cash Equivalents and Short-Term Investments | 165.92M | 216.89M | 322.40M | 574.96M | 632.14M | 551.27M |
| Total Debt | 270.88M | 35.58M | 376.69M | 610.97M | 585.26M | 575.22M |
| Total Liabilities | 344.13M | 397.87M | 431.04M | 697.57M | 1.38B | 1.37B |
| Stockholders Equity | 211.56M | 212.38M | 325.29M | 416.75M | 545.22M | 315.50M |
Cash Flow | ||||||
| Free Cash Flow | -51.87M | -70.72M | -22.19M | 60.67M | 518.89M | 353.72M |
| Operating Cash Flow | -39.52M | -57.57M | 7.46M | 126.22M | 535.98M | 368.57M |
| Investing Cash Flow | -12.71M | -31.41M | -24.32M | -122.31M | -267.61M | 105.66M |
| Financing Cash Flow | -66.83M | -16.50M | -235.71M | -61.09M | -187.50M | -159.05M |
Maravai Lifesciences Holdings Technical Analysis
Positive
3.39
Price Trends
4.93
Positive
4.10
Positive
3.74
Positive
Market Momentum
0.34
Positive
66.35
Neutral
30.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRVI, the sentiment is Positive. The current price of 3.39 is below the 20-day moving average (MA) of 5.69, below the 50-day MA of 4.93, and below the 200-day MA of 3.74, indicating a bullish trend. The MACD of 0.34 indicates Positive momentum. The RSI at 66.35 is Neutral, neither overbought nor oversold. The STOCH value of 30.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MRVI.
Maravai Lifesciences Holdings Risk Analysis
Maravai Lifesciences Holdings disclosed 74 risk factors in its most recent earnings report. Maravai Lifesciences Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Maravai Lifesciences Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $1.54B | -8.24 | -44.72% | ― | -15.35% | 37.09% | |
56 Neutral | $1.07B | ― | -141.95% | ― | 5.37% | -60.20% | |
53 Neutral | $1.86B | -28.86 | -19.83% | ― | ― | -15.44% | |
52 Neutral | $4.52B | -12.72 | -43.94% | ― | 39.04% | 29.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.01B | -1.96 | 1870.38% | ― | -50.80% | 14.80% | |
44 Neutral | $1.34B | -4.97 | -45.27% | ― | -72.09% | -754.83% |
* Healthcare Sector Average
MRVI
Maravai Lifesciences Holdings
6.09
3.42
128.09%
KURA
Kura Oncology
11.45
5.10
80.31%
IMTX
Immatics
9.68
3.57
58.43%
RLAY
Relay Therapeutics
20.01
16.45
461.94%
IVA
Inventiva
4.30
0.84
24.28%
GHRS
GH Research
26.51
10.02
60.76%
Maravai Lifesciences Holdings Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Maravai LifeSciences Refinances Debt, Extends Credit Facilities
Positive
Jun 3, 2026
On June 2, 2026, Maravai LifeSciences subsidiaries Maravai Intermediate Holdings and Maravai Topco entered into a new credit agreement that establishes a $150 million term loan and a $30 million revolving credit facility, both maturing on June 2, ...
Executive/Board ChangesShareholder Meetings
Maravai Lifesciences Shareholders Back Board, Pay, Auditor
Positive
May 29, 2026
On May 26, 2026, Maravai LifeSciences Holdings, Inc. held its 2026 Annual Meeting of Shareholders, where 236,082,968 of 258,180,170 outstanding common shares were represented, establishing a quorum and reflecting strong shareholder participation. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.